

Jodie Hay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3353359/publications.pdf>

Version: 2024-02-01

20
papers

5,948
citations

687363

13
h-index

752698

20
g-index

24
all docs

24
docs citations

24
times ranked

12341
citing authors

#	ARTICLE	IF	CITATIONS
1	Symptoms and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Positivity in the General Population in the United Kingdom. <i>Clinical Infectious Diseases</i> , 2022, 75, e329-e337.	5.8	20
2	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. <i>Nature Medicine</i> , 2022, 28, 1072-1082.	30.7	147
3	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	13.7	3,887
4	Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey. <i>Lancet Public Health, The</i> , 2021, 6, e30-e38.	10.0	147
5	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	13.7	540
6	Ct threshold values, a proxy for viral load in community SARS-CoV-2 cases, demonstrate wide variation across populations and over time. <i>ELife</i> , 2021, 10, .	6.0	91
7	Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. <i>Nature Microbiology</i> , 2021, 6, 1140-1149.	13.3	254
8	Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. <i>Nature Medicine</i> , 2021, 27, 2127-2135.	30.7	450
9	Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. <i>Nature Communications</i> , 2021, 12, 6250.	12.8	88
10	Tracking the Emergence of SARS-CoV-2 Alpha Variant in the United Kingdom. <i>New England Journal of Medicine</i> , 2021, 385, 2582-2585.	27.0	49
11	Collaboration of MYC and RUNX2 in lymphoma simulates T cell receptor signaling and attenuates p53 pathway activity. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 18332-18345.	2.6	7
12	Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	1
13	mTORC1 activity is essential for erythropoiesis and B cell lineage commitment. <i>Scientific Reports</i> , 2019, 9, 16917.	3.3	7
14	Disrupting MLV integrase:BET protein interaction biases integration into quiescent chromatin and delays but does not eliminate tumor activation in a MYC/Runx2 mouse model. <i>PLoS Pathogens</i> , 2019, 15, e1008154.	4.7	10
15	AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival. <i>Clinical Cancer Research</i> , 2019, 25, 1574-1587.	7.0	19
16	RUNX2-mediated growth arrest and senescence are attenuated by diverse mechanisms in cells expressing RUNX1 fusion oncoproteins. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 2750-2762.	2.6	11
17	The RUNX Genes as Conditional Oncogenes: Insights from Retroviral Targeting and Mouse Models. <i>Advances in Experimental Medicine and Biology</i> , 2017, 962, 247-264.	1.6	14
18	RUNX oncoproteins and miRNA networks. <i>Oncotarget</i> , 2017, 8, 62818-62819.	1.8	1

#	ARTICLE	IF	CITATIONS
19	Addiction to <i>Runx1</i> is partially attenuated by loss of p53 in the $\hat{E}^{1/4}$ -Myc lymphoma model. <i>Oncotarget</i> , 2016, 7, 22973-22987.	1.8	9
20	Prognostic and therapeutic relevance of $\hat{c}\hat{\epsilon}$ -FLIP in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 188-198.	2.5	39